Emerging, non-PCV13 serotypes 11A and 35B of Streptococcus pneumoniae show high potential for biofilm formation in vitro

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Domenech, Mirian ^a,b   Damián, Diana ^a   Ardanuy, Carmen ^b,c   Liñares, Josefina ^b,c   Fenoll, Asunción ^d   García, Ernesto ^a,b  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; BACTERIAL POLYSACCHARIDE; PNEUMOCOCCUS VACCINE;

ARTICLE; BACTERIAL CAPSULE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM EXAMINATION; BACTERIUM TRANSFORMATION; BIOFILM; DISEASE SURVEILLANCE; GENETIC TRANSFORMATION; IN VITRO STUDY; NONHUMAN; PREDICTION; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; CHEMISTRY; CLASSIFICATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM;

BIOFILMS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; SEROGROUP; STREPTOCOCCUS PNEUMONIAE;

EID: 84947457054     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125636     Document Type: Article

References (47)

1. Crook DW, Brueggemann AB, Sleeman KL, Peto TEA. Pneumococcal carriage. In: Tuomanen E, Mitchell TJ, Morrison DA, Spratt BG, editors. The Pneumococcus. Washington, D. C.: ASM Press; 2004. pp. 136-147.
2. Henriques-Normark B, Tuomanen EI. The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harb Perspect Med. 2013;3:a010215. doi: 10.1101/cshperspect.a010215 PMID: 23818515
3. Grabenstein JD, Klugman KP. A century of pneumococcal vaccination research in humans. Clin Microbiol Infect. 2012;18:15-24. doi: 10.1111/j.1469-0691.2012.03943.x PMID: 22882735
4. Hausdorff W, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr. 2010;10:4. doi: 10.1186/1471-2431-10-4 PMID: 20122261
5. Ardanuy C, Marimón JM, Calatayud L, Giménez M, Alonso M, Grau I, et al. Epidemiology of invasive pneumococcal disease in older people in Spain (2007-2009): implications for future vaccination strategies. PLoS One. 2012;7:e43619. doi: 10.1371/journal.pone.0043619 PMID: 22928005
6. Steens A, Bergsaker MAR, Aaberge IS, Rønning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013;31:6232-6238. doi: 10.1016/j.vaccine.2013.10.032 PMID: 24176490
7. Camilli R, Daprai L, Cavrini F, Lombardo D, D'Ambrosio F, Del Grosso M, et al. Pneumococcal carriage in young children one year after introduction of the 13-valent conjugate vaccine in Italy. PLoS One. 2013;8:e76309. doi: 10.1371/journal.pone.0076309 PMID: 24124543
8. Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013;32:203-207. doi: 10.1097/INF.0b013e318275614b PMID: 23558320
9. Domenech M, Araújo-Bazán L, García E, Moscoso M. In vitro biofilm formation by Streptococcus pneumoniae as a predictor of post-vaccination emerging serotypes colonizing the human nasopharynx. Environ Microbiol. 2014;16:1193-1201. doi: 10.1111/1462-2920.12370 PMID: 24373136
10. World Health Organization. Review of serotype replacement in the setting of 7-valent pneumococcal conjugate vaccine (PCV-7) use and implications for the PCV10/PCV13 era. Wkly Epidemiol Rec. 2012;87:12-13.
11. Moscoso M, García E, López R. Biofilm formation by Streptococcus pneumoniae: role of choline, extracellular DNA, and capsular polysaccharide in microbial accretion. J Bacteriol. 2006;188:7785-7795. PMID: 16936041
12. Muñoz R, Mollerach M, López R, García E. Characterization of the type 8 capsular gene cluster of Streptococcus pneumoniae. J Bacteriol. 1999;181:6214-6219. PMID: 10498742
13. Kamerling JP. Pneumococcal polysaccharides: a chemical view. In: Tomasz A, editor. Streptococcus pneumoniae Molecular Biology & Mechanisms of Disease. Larchmont, NY: Mary Ann Liebert, Inc; 2000. pp. 81-114.
14. Domenech M, García E, Moscoso M. Versatility of the capsular genes during biofilm formation by Streptococcus pneumoniae. Environ Microbiol. 2009;11:2542-2555. doi: 10.1111/j.1462-2920.2009. 01979.x PMID: 19549167
15. Domenech M, García E, Moscoso M. Biofilm formation in Streptococcus pneumoniae. Microb Biotechnol. 2012;5:455-465. doi: 10.1111/j.1751-7915.2011.00294.x PMID: 21906265
16. Goldblatt D, Ramakrishnan M, O'Brien K. Using the impact of pneumococcal vaccines on nasopharyngeal carriage to aid licensing and vaccine implementation; A Pneumocarr meeting report March 27-28, 2012, Geneva. Vaccine. 2013;32:146-152. doi: 10.1016/j.vaccine.2013.06.040 PMID: 23933374
17. Bogaert D, van Belkum A, Sluijter M, Luijendijk A, de Groot R, Rümke HC, et al. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet. 2004;363:1871-1872. PMID: 15183627
18. Simell B, Auranen K, Käyhty H, Goldblatt D, Dagan R, O'Brien KL, et al. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines. 2012;11:841-855. PMID: 22913260
19. Saha S, Modak JK, Naziat H, Al-Emran HM, Chowdury M, Islam M, et al. Detection of co-colonization with Streptococcus pneumoniae by algorithmic use of conventional and molecular methods. Vaccine. 2015;33:713-718. doi: 10.1016/j.vaccine.2014.11.040 PMID: 25523524
20. Marks LR, Reddinger RM, Hakansson AP. High levels of genetic recombination during nasopharyngeal carriage and biofilm formation in Streptococcus pneumoniae. mBio. 2012;3:e00200-00212. doi: 10. 1128/mBio.00200-12 PMID: 23015736
21. van Hoek AJ, Sheppard CL, Andrews NJ, Waight PA, Slack MPE, Harrison TG, et al. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine. 2014;32:4349-4355. doi: 10.1016/j.vaccine.2014.03.017 PMID: 24657717
22. Skinner JM, Indrawati L, Cannon J, Blue J, Winters M, MacNair J, et al. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. Vaccine. 2011;29:8870-8876. doi: 10.1016/j.vaccine.2011.09.078 PMID: 21964055
23. Martin JM, Hoberman A, Paradise JL, Barbadora KA, Shaikh N, Bhatnagar S, et al. Emergence of Streptococcus pneumoniae serogroups 15 and 35 in nasopharyngeal cultures from young children with acute otitis media. Pediatr Infect Dis J. 2014;33:e286-e290. doi: 10.1097/INF. 0000000000000445 PMID: 24911895
24. McElligott M, Vickers I, Cafferkey M, Cunney R, Humphreys H. Non-invasive pneumococcal serotypes and antimicrobial susceptibilities in a paediatric hospital in the era of conjugate vaccines. Vaccine. 2014;32:3495-3500. doi: 10.1016/j.vaccine.2014.04.047 PMID: 24795223
25. Li Y, Weinberger DM, Thompson CM, Trzciński K, Lipsitch M. Surface charge of Streptococcus pneumoniae predicts serotype distribution. Infect Immun. 2013;81:4519-4524. doi: 10.1128/IAI.00724-13 PMID: 24082068
26. Weinberger DM, Trzciński K, Lu Y-J, Bogaert D, Brandes A, Galagan J, et al. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog. 2009;5:e1000476. doi: 10. 1371/journal.ppat.1000476 PMID: 19521509
27. Calix JJ, Brady AM, Du VY, Saad JS, Nahm MH. Spectrum of pneumococcal serotype 11A variants results from incomplete loss of capsule O-acetylation. J Clin Microbiol. 2014;52:758-765. doi: 10.1128/JCM.02695-13 PMID: 24352997
28. Brady AM, Calix JJ, Yu J, Geno KA, Cutter GR, Nahm MH. Low invasiveness of pneumococcal serotype 11A is linked to ficolin-2 recognition of O-acetylated capsule epitopes and lectin complement pathway activation. J Infect Dis. 2014;210:1155-1165. doi: 10.1093/infdis/jiu195 PMID: 24683196
29. del Amo E, Selva L, de Sevilla MF, Ciruela P, Brotons P, Triviño M, et al. Estimation of the invasive disease potential of Streptococcus pneumoniae in children by the use of direct capsular typing in clinical specimens. Eur J Clin Microbiol Infect Dis. 2014: doi:0.1007/s10096-10014-12280-y.
30. Marks LR, Davidson BA, Knight PR, Hakansson AP. Interkingdom signaling induces Streptococcus pneumoniae biofilm dispersion and transition from asymptomatic colonization to disease. mBio. 2013;4:e00438-00413. doi: 10.1128/mBio.00438-13 PMID: 23882016
31. Charalambous BM, Leung MH. Pneumococcal sepsis and nasopharyngeal carriage. Curr Opin Pulm Med. 2012;18:222-227. doi: 10.1097/MCP.0b013e328352103b PMID: 22343427
32. Vernatter J, Pirofski L-a. Current concepts in host-microbe interaction leading to pneumococcal pneumonia. Curr Opin Infect Dis. 2013;26:277-283. doi: 10.1097/QCO.0b013e3283608419 PMID: 23571695
33. van Gils EJM, Hak E, Veenhoven RH, Rodenburg GD, Bogaert D, Bruin JP, et al. Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial. PLoS One. 2011;6:e20229. doi: 10.1371/journal.pone.0020229 PMID: 21695210
34. van den Bergh MR, Biesbroek G, Rossen JWA, de Steenhuijsen Piters WA, Bosch A A TM, van Gils EJM, et al. Associations between pathogens in the upper respiratory tract of young children: interplay between viruses and bacteria. PLoS One. 2012;7:e47711. doi: 10.1371/journal.pone.0047711 PMID: 23082199
35. Hammitt LL, Akech DO, Morpeth SC, Karani A, Kihuha N, Nyongesa S, et al. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Health. 2014;2:e397-e405. doi: 10.1016/S2214-109X (14) 70224-4 PMID: 25103393
36. Nzenze SA, Shiri T, Nunes MC, Klugman KP, Kahn K, Twine R, et al. Temporal association of infant immunisation with pneumococcal conjugate vaccine on the ecology of Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus nasopharyngeal colonisation in a rural South African community. Vaccine. 2014;32:5520-5530. doi: 10.1016/j.vaccine.2014.06.091 PMID: 25101982
37. Nunes MC, Jones SA, Groome MJ, Kuwanda L, Van Niekerk N, von Gottberg A, et al. Acquisition of Streptococcus pneumoniae in South African children vaccinated with 7-valent pneumococcal conjugate vaccine at 6, 14 and 40 weeks of age. Vaccine. 2015;33:628-634. doi: 10.1016/j.vaccine. 2014.12.023 PMID: 25541213
38. Auranen K, Rinta-Kokko H, Goldblatt D, Nohynek H, O'Brien KL, Satzke C, et al. Colonisation endpoints in Streptococcus pneumoniae vaccine trials. Vaccine. 2013;32:153-158. doi: 10.1016/j. vaccine.2013.08.061 PMID: 24016803
39. Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Klugman KP. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med. 2014;2:387-394. doi: 10.1016/S2213-2600 (14) 70032-3 PMID: 24815804
40. Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O'Brien KL, for the AGEDD Adult Pneumococcal Burden Study Team. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013;8:e60273. doi: 10.1371/journal. pone.0060273 PMID: 23565216
41. Feldman C, Anderson R. Recent advances in our understanding of Streptococcus pneumoniae infection. F1000Prime Rep. 2014;6:82. doi: 10.12703/P6-82 PMID: 25343039
42. Mendes RE, Biek D, Critchley IA, Farrell DJ, Sader HS, Jones RN. Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agents. Antimicrob Agents Chemother. 2014;58:4923-4927. doi: 10.1128/AAC.02976-14 PMID: 24867974
43. Richter SS, Diekema DJ, Heilmann KP, Dohrn CL, Riahi F, Doern GV. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother. 2014;58:6484-6489. doi: 10.1128/AAC.03344-14 PMID: 25136018
44. Domenech A, Tirado-Vélez JM, Fenoll A, Ardanuy C, Yuste J, Liñares J, et al. Fluoroquinolone-resistant pneumococci: dynamics of serotypes and clones in Spain in 2012 compared with those from 2002 and 2006. Antimicrob Agents Chemother. 2014;58:2393-2399. doi: 10.1128/AAC.02669-13 PMID: 24514095
45. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360:244-256. doi: 10.1056/NEJMoa0800836 PMID: 19144940
46. Chiba N, Morozumi M, Shouji M, Wajima T, Iwata S, Ubukata K, et al. Changes in capsule and drug resistance of pneumococci after introduction of PCV7, Japan, 2010-2013. Emerg Infect Dis. 2014;20:1132-1139. doi: 10.3201/eid2007.131485 PMID: 24960150
47. Grau I, Ardanuy C, Calatayud L, Schulze MH, Liñares J, Pallares R. Smoking and alcohol abuse are the most preventable risk factors for invasive pneumonia and other pneumococcal infections. Int J Infect Dis. 2014;25:59-64. doi: 10.1016/j.ijid.2013.12.013 PMID: 24853638